Helix BioPharma Corp. Extends Date of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing

(TheNewswire)

February 2 4 , 2025 - (Toronto, Ontario) – TheNewswire – Helix BioPharma Corp. (TSX: “HBP”,OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the“Company”), a clinical-stage oncology company shaping a nearfuture where today’s hard-to-treat cancers are vincible, announcesthat its Annual General and Special Meeting (the “Meeting”) forthe year ended July 31, 2024, that was to be held by January 31, 2025,has been extended to March 26, 2025 to provide additional time to seekshareholder approval with respect to its proposed asset acquisitionsfrom Laevoroc Immunology AG and Laevoroc Chemotherapy AG (the “AssetAcquisitions”), as well as a proposed financing utilizing adraw-down subscription facility structure.

The Company has applied to the Ontario Superior Court of Justice foran order under section 133(3) of the Canada Business Corporations Actpermitting it to hold the Meeting by March 26, 2025. The applicationis scheduled to be heard on Wednesday, February 26, 2025, at 10:00 am,by videoconference. Any interested party may attend the hearing, and,if the court permits, make submissions.

The Company received an acknowledgement from the Toronto StockExchange to hold the Meeting on or before March 26, 2025. The Companyexpects to hold a further annual general meeting before January 31,2026 as is required under applicable corporate and securities laws.

For more information on the Asset Acquisitions, please see theCompany’s news releases dated November 29, 2024, December 2, 2024,December 6, 2024.

The Notice of Meeting, Management Information Circular, FinancialStatements Request Form, Form of Proxy and Voting Instruction Form(the “Meeting Materials”) will be mailed to shareholders andposted on the Company’s profile on SEDAR+ at www.sedarplus.ca on orbefore February 24, 2025.

Shareholders of record as of January 31, 2025, are entitled to votetheir shares of the Company at the Meeting. The Company encourages itsshareholders to vote in advance of the Meeting using the instructionson the Voting Instruction Form or the Form of Proxy that will bemailed to them with the Meeting Materials. Shareholders are remindedthat proxies must be received by 10 a.m. (EST) on March 24, 2025.

For more information, pleasecontact:

Helix BioPharma Corp.

Bay Adelaide Centre - North Tower

40 Temperance Street, Suite 2

Toronto, ON M5H 0B4

Tel: 604-428-7050

Jacek Antas, Director

corporate@helixbiopharma.com

About Helix BioPharma Corp.
Helix BioPharma Corp. is an oncology company shaping a near futurewhere today’s hard-to-treat cancers are made vincible by noveltherapies that rise to the challenge. The Company innovates fromstrength to tackle cancer’s biggest, most urgent challenges with adiverse pipeline of drug candidates with great potential and a headstart, honed into first- and best-in-class oncology medicines. Itspipeline is spearheaded by a clinical-stage proprietary technologyplatform of bioconjugates that score with precision against prevalentCEACAM6-expressing solid tumours. Its lead candidate, Tumour DefenceBreakerTM L-DOS47, is a clinical-stage antibody-enzyme conjugate (AEC)that neutralizes the microenvironment of common, hard-to-treat solidtumours, taking the brakes off anti-cancer immunity and delivering agame-changing assist to today’s front-running anticancer therapies.L-DOS47 has completed Phase Ib studies in non-small cell lung cancer(NSCLC), with novel strategically designed bi-specific ADCs targetingCEACAM6 in discovery. Helix is listed on the TSX under the symbol“HBP”, on OTC PINK under the symbol “HBPCD” and on FWB underthe symbol “HBP0”.

Forward-Looking Statements and Risksand Uncertainties

This news release contains forward-looking statements and information(collectively, “forward looking statements”) within the meaning ofapplicable Canadian securities laws. Forward-looking statements arestatements and information that are not historical facts but insteadinclude statements regarding plans, goals, objectives, intentions andexpectations with respect to the closing of the Asset Acquisitions,the proposed financing, the date of the court application and the dateof the Meeting, the ability of the Company to obtain an order from theOntario Superior Court of Justice to extend the Meeting, and theCompany’s future business, operations, research and development.Forwardlooking statements can further be identified by the use offorward-looking terminology such as “will”, “plans”,“expects”, or the negative thereof or any other variations thereonor comparable terminology referring to future events or results, orthat events or conditions “will”, “may”, “could”, or“should” occur or be achieved, or comparable terminology referringto future events or results. Forward-looking statements are statementsabout the future and are inherently uncertain and are necessarilybased upon a number of estimates and assumptions that are alsouncertain. Although the Company believes that the expectationsreflected in such forward-looking statements are reasonable, suchstatements involve risks and uncertainties, and undue reliance shouldnot be placed on such statements. Forward-looking statements areintended to provide information about management’s current plans andexpectations regarding future operations and may not be appropriatefor other purposes. Certain material factors, estimates or assumptionshave been applied in making forward-looking statements in this newsrelease. The Company’s actual results could differ materially fromthose anticipated in the forward-looking statements contained in thisnews release as a result of numerous known and unknown risks anduncertainties, including the risk factors discussed in the Company’scontinuous disclosure record filed under the Company’s profile onSEDAR+ at www.sedarplus.ca from time to time. Forward-lookingstatements and information are based on the beliefs, assumptions,opinions and expectations of Helix’s management on the date of thisnew release, and the Company does not assume any obligation to updateany forward-looking statement or information should those beliefs,assumptions, opinions or expectations, or other circumstances change,except as required

Copyright (c) 2025 TheNewswire - All rights reserved.